Prelude Therapeutics Incorporated
PRLDNASDAQHealthcare● Active
$3.99
+$0.15(+3.91%)
Market Cap$227161780
P/E Ratio—
52W High$5.54
52W Low$0.75
Prelude Therapeutics Incorporated (PRLD) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · PRLD · as of 2026-06-10
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | ($99.50M) | ($127.17M) | ($121.83M) | ($115.44M) | ($111.69M) |
| Depreciation & Amort. | $1.34M | $1.77M | $1.17M | $1.32M | $0.92M |
| Stock-Based Comp. | $11.91M | $21.34M | $25.62M | $25.14M | $20.93M |
| Change in Working Capital | $28.41M | $4.22M | ($10.48M) | $0.93M | $3.63M |
| Net Cash from Operations | ($56.30M) | ($102.89M) | ($107.06M) | ($83.73M) | ($83.53M) |
| Investing Activities | |||||
| Capital Expenditure | ($0.07M) | ($0.76M) | ($3.51M) | ($3.02M) | ($2.32M) |
| Purchases of Investments | ($100.87M) | ($52.69M) | ($221.63M) | ($119.22M) | ($261.48M) |
| Sales of Investments | $154.39M | $143.65M | $190.50M | $203.93M | $0.00M |
| Net Cash from Investing | $53.46M | $90.19M | ($34.65M) | $81.69M | ($263.80M) |
| Financing Activities | |||||
| Common Stock Repurchased | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Dividends Paid | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Debt Issued / Repaid | ($0.21M) | ($0.40M) | $0.00M | $0.00M | $0.00M |
| Net Cash from Financing | $24.82M | ($0.12M) | $136.40M | $0.81M | $164.90M |
| Free Cash Flow | |||||
| Free Cash Flow | ($56.37M) | ($103.65M) | ($110.58M) | ($86.75M) | ($85.85M) |
| FCF Margin %(computed) | -464.32% | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-10 · USD · M
Explore more Prelude Therapeutics Incorporated data
About Prelude Therapeutics Incorporated (PRLD) Cash Flow Statement
Prelude Therapeutics Incorporated generated operating cash flow of ($0.06B) and free cash flow of ($0.06B) for 2025 — a FCF margin of -464.32%. Capital expenditure was ($0.00B).
Frequently asked questions
PRLD · 4 questionsPrelude Therapeutics Incorporated generated free cash flow of ($0.06B) for 2025, up 45.6% year-over-year.
PRLD free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10